Profile: Antares Pharma Inc (ATRS.O)
18 Jan 2017
Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.
The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector. OTREXUP, which utilizes VIBEX auto injector, is indicated for adults with severe active rheumatoid arthritis (RA), children with active polyarticular juvenile idiopathic arthritis (pJIA) and adults with severe recalcitrant psoriasis. It has marketing rights for OTREXUP across the world and to commercialize OTREXUP on its own in the United States for the treatment of RA. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It also offers Vibex QS M. It has positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company's ongoing, multi-center, phase III clinical study (QST-13-003) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot auto injector in testosterone deficient adult males The Company is also developing VIBEX with Sumatriptan for the acute treatment of migraines.
The Company's development projects in collaboration with Teva Pharmaceutical Industries, Ltd. (Teva) include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. It also makes a reusable, needle-free, spring-action injector device known as ZOMA-Jet or Twin-Jector, which is marketed for use with hGH. Ferring Pharmaceuticals BV (Ferring) commercializes its needle-free injection system with their over four milligrams and approximately 10 milligrams hGH formulations marketed as Zomajet 2 Vision and Zomajet Vision X across the world. The Company has over two gel-based products, which are commercialized through various partners of the Company. Its oxybutynin gel 3% product, Gelnique, is used for the treatment of overactive bladder (OAB), and is being marketed in the United States under a licensing agreement with Actavis plc (Actavis). Elestrin (estradiol gel) is marketed by Meda Pharmaceuticals, Inc. (Meda) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan, Inc., Roxane, Bedford Laboratories, APP Pharmaceuticals, Hospira, Accord Healthcare, Abbvie, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc, Pfizer, Inc., Actavis PLC, Sandoz, Inc., F. Hoffmann-La Roche AG, Janssen Pharmaceuticals, Merck & Co., Inc., Impax Laboratories, GlaxoSmithKline, Allergan, Novo Nordisk, Inc, Roche/Genentech, EMD Serono, Inc., Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc. and The Medical House PLC.
Antares Pharma Inc
SUITE 300, 100 PRINCETON SOUTH
EWING NJ 8628